Intellectual Property Rights-Articles-open-access

High Impact List of Articles

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence Philip Ames & Anat Galor

  Drug Evaluation: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• What is the potential of Rho kinase inhibitors in the treatment of glaucoma? Sarah Van de Velde

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Stem cell clinical trials: toward cell-based therapy for retinal degenerations Henry Klassen

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Nocturia, of clinical importance Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski

  Editorial: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

• Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective David Schoenfeld

  Clinical Trail Perspective: Clinical Investigation

Relevant Topics in Clinical